Jefferies Sees Hemlibra-Like Potential in Hemab Therapeutics, Starts Coverage with Buy Rating
Hemab targets rare bleeding diseases with new treatments, strong cash, and big growth potential, with analysts seeing ~50% upside.
NOTRELOAD AI
Tectonic Therapeutics Gets Strong Buy Upgrade: Two Potential Blockbusters in Focus
Raymond James upgraded Tectonic Therapeutics to Strong Buy and raised its price target to $81. Analyst highlights the potential of TX45 and TX2100 as two blockbuster candidates at a low valuation.
Curium Makes $7 Billion Takeover Offer for Lantheus Holdings
Lantheus is in talks to be bought by Curium for about $7B. No deal yet. Stock rose. Deal would be big in nuclear medicine.
Gilead’s Hepcludex Becomes First Approved Treatment for Chronic Hepatitis Delta
FDA approves first HDV drug Hepcludex in US after prior rejection; lowers virus, but needs monitoring for safety risks.
Uber Eyeing Full Takeover of Delivery Hero
Uber is exploring a full acquisition of European food delivery giant Delivery Hero. The deal could boost growth but faces regulatory review in Europe and involves a high financial commitment.
Dell Stock Jumps as Analysts Expect Strong AI Earnings Beat
Dell stock jumps on AI hype, with strong growth expected. Other tech firms like HP and Lenovo also rise on booming AI demand.